434 related articles for article (PubMed ID: 34337077)
21. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.
Jiang H; Zhang W; Shang P; Zhang H; Fu W; Ye F; Zeng T; Huang H; Zhang X; Sun W; Man-Yuen Sze D; Yi Q; Hou J
Mol Oncol; 2014 Mar; 8(2):297-310. PubMed ID: 24388357
[TBL] [Abstract][Full Text] [Related]
22. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
[TBL] [Abstract][Full Text] [Related]
23. Cytokines induced memory-like NK cells engineered to express CD19 CAR exhibit enhanced responses against B cell malignancies.
He B; Mai Q; Pang Y; Deng S; He Y; Xue R; Xu N; Zhou H; Liu X; Xuan L; Li C; Liu Q
Front Immunol; 2023; 14():1130442. PubMed ID: 37207215
[TBL] [Abstract][Full Text] [Related]
24. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.
Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS
Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081
[TBL] [Abstract][Full Text] [Related]
25. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ
Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477
[TBL] [Abstract][Full Text] [Related]
26. Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.
Halim L; Das KK; Larcombe-Young D; Ajina A; Candelli A; Benjamin R; Dillon R; Davies DM; Maher J
Front Immunol; 2022; 13():836549. PubMed ID: 35222427
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies.
Tanaka J
Hematol Oncol; 2021 Feb; 39(1):11-19. PubMed ID: 32905618
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
29. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
Ureña-Bailén G; Dobrowolski JM; Hou Y; Dirlam A; Roig-Merino A; Schleicher S; Atar D; Seitz C; Feucht J; Antony JS; Mohammadian Gol T; Handgretinger R; Mezger M
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361619
[TBL] [Abstract][Full Text] [Related]
30. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
31. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
Chaudhry K; Dowlati E; Bollard CM
Expert Rev Clin Immunol; 2021 Jun; 17(6):643-659. PubMed ID: 33821731
[No Abstract] [Full Text] [Related]
33. NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells.
Zhuang X; Long EO
Front Immunol; 2022; 13():840844. PubMed ID: 35585985
[TBL] [Abstract][Full Text] [Related]
34. Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4.
Jamali A; Hadjati J; Madjd Z; Mirzaei HR; Thalheimer FB; Agarwal S; Bonig H; Ullrich E; Hartmann J
Front Immunol; 2020; 11():2028. PubMed ID: 32983147
[TBL] [Abstract][Full Text] [Related]
35. Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect
Silvestre RN; Eitler J; de Azevedo JTC; Tirapelle MC; Fantacini DMC; de Souza LEB; Swiech K; Covas DT; Calado RT; Montero PO; Malmegrim KCR; Figueiredo ML; Tonn T; Picanço-Castro V
Front Immunol; 2023; 14():1226518. PubMed ID: 37818365
[TBL] [Abstract][Full Text] [Related]
36. Genetic Engineering and Enrichment of Human NK Cells for CAR-Enhanced Immunotherapy of Hematological Malignancies.
Soldierer M; Bister A; Haist C; Thivakaran A; Cengiz SC; Sendker S; Bartels N; Thomitzek A; Smorra D; Hejazi M; Uhrberg M; Scheckenbach K; Monzel C; Wiek C; Reinhardt D; Niktoreh N; Hanenberg H
Front Immunol; 2022; 13():847008. PubMed ID: 35464442
[TBL] [Abstract][Full Text] [Related]
37. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.
Altvater B; Landmeier S; Pscherer S; Temme J; Schweer K; Kailayangiri S; Campana D; Juergens H; Pule M; Rossig C
Clin Cancer Res; 2009 Aug; 15(15):4857-66. PubMed ID: 19638467
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
Yilmaz A; Cui H; Caligiuri MA; Yu J
J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]